Unicycive Net Income Per Share from 2010 to 2024

UNCY Stock  USD 0.68  0.09  15.25%   
Unicycive Therapeutics Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to -1.31 in 2024. During the period from 2010 to 2024, Unicycive Therapeutics Net Loss regression line of annual values had significance of  0.0005 and arithmetic mean of (0.41). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(1.24)
Current Value
(1.31)
Quarterly Volatility
0.45902564
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 77.9 K, Net Interest Income of 429.4 K or Depreciation And Amortization of 386.4 K, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Unicycive Therapeutics Correlation against competitors.
For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Latest Unicycive Therapeutics' Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Unicycive Therapeutics over the last few years. It is Unicycive Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unicycive Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

Unicycive Net Income Per Share Regression Statistics

Arithmetic Mean(0.41)
Coefficient Of Variation(111.59)
Mean Deviation0.38
Median(0.14)
Standard Deviation0.46
Sample Variance0.21
Range1.169
R-Value(0.79)
Mean Square Error0.09
R-Squared0.62
Significance0.0005
Slope(0.08)
Total Sum of Squares2.95

Unicycive Net Income Per Share History

2024 -1.31
2023 -1.24
2022 -1.2
2021 -0.71
2020 -0.16
2019 -0.27

About Unicycive Therapeutics Financial Statements

Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' Net Income Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss(1.24)(1.31)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.